CBS News is reporting that a implanted artificial retina has been approved by European health officials.
The device is offering partial sight to people who have become blind due to the condition retinitis pigmentosa.
The report describes how a man who had lost his sight completely at age 35 is now able to make out shapes and outlines. As described by CBS: “The device starts with a tiny video camera mounted in a pair of glasses. A transmitter in the glasses sends the images to chip implanted on the back of the damaged eye. There, 60 electrodes send the image along the optic nerve straight to the brain.”
An implanted microchip placed beneath the retina of the eye has enabled blind people to see again.
In a paper published in The Procedings of the Royal Society B researchers describe how three patients suffering from hereditary retinal dystrophy regained the ability to identify objects and people and even read words printed in large letters. The technology involves that natural projection of images through the eye’s lens onto a chip placed under the transparent retina.
Scientists at UC Irvine have created an early stage retina from human embryonic stem cells. It is the first three-dimensional tissue structure to be made from stem cells and bring us closer to the development of transplant-ready retinas to treat eye disorders such as retinitis pigmentosa and macular degeneration that affect millions. Researchers managed to employ a technique that allowed them to create the multiple cell types necessary for the retina.
A small study by Japanese researchers demonstrates an increased blood supply to the retina upon stimulation of certain acupuncture points. Needles were inserted near the posterior base of the thumbs of volunteers while investigators used a laser to scan the retinal blood flow. Both volume and velocity increased in these patients. The work was done at the ophthalmology department at Kyoto Prefectural University of Medicine.
Reported by Dr. Kazuhiko Mori at the annual meeting of the Association for Vision and Ophthalmology in Fort Lauderdale this past May.
In a 48-week intervention trial, researchers tested Lutein supplementation for vision protective-function in patients with retinitis pigmentosa (RP). The conclusion of the study was as follows: “Comparing the development of vision measures against the natural loss expected to occur over the course of the 48 weeks, most measures showed reduced decline, and these reductions were significant for normal illumination”.
Ophthalmology (BMC Ophthalmology 2006, 6:23)
For more information and specific research studies by eye condition on nutrition and vision, go to <a href=”http://www.naturaleyecare.com”>Natural Eye Care </a>
Scientists through the US Department of Energy are testing artificial retinas that they hope can restore partial sight to people who’ve lost their vision to the most common causes of blindness.
The Sylmar, Calif., company produced the devices for the U.S. Energy Department’s Artificial Retina Project. The department has been engaged in biological research since the atomic bomb tests of the 1950s raised fears of radiation poisoning.
The current version is being tested on 17 blind people in the U.S. and Europe, and more patients are being enrolled. At a retina conference in October, patients reported improvements in orientation and mobility. They were able to find a door from 20 feet away and to follow a line on the floor for 20 feet.
Meanwhile, researchers in the Energy Department’s National Laboratories are creating a third-generation artificial retina. Much smaller than its predecessors, the device will contain 200 or more electrodes on a thin, flexible film that curves to fit the shape of the retina. Human tests are scheduled to begin in 2011.
For more information and specific research studies by eye condition including nutrition and vision research, go to <a href=”http://www.naturaleyecare.com”>Natural Eye Care </a>
Scientists through the US Department of Energy are testing artificial retinas that they hope can restore partial sight to people who’ve lost their vision to the most common causes of blindness.
The Sylmar, Calif., company produced the devices for the U.S. Energy Department’s Artificial Retina Project. The department has been engaged in biological research since the atomic bomb tests of the 1950s raised fears of radiation poisoning.
The current version is being tested on 17 blind people in the U.S. and Europe, and more patients are being enrolled. At a retina conference in October, patients reported improvements in orientation and mobility. They were able to find a door from 20 feet away and to follow a line on the floor for 20 feet, Mech reported.
Meanwhile, researchers in the Energy Department’s National Laboratories are creating a third-generation artificial retina. Much smaller than its predecessors, the device will contain 200 or more electrodes on a thin, flexible film that curves to fit the shape of the retina. Human tests are scheduled to begin in 2011.
In a 48-week intervention trial, researchers tested Lutein supplementation
for vision protective-function in patients with retinitis pigmentosa (RP). The conclusion of the study was as follows: “Comparing the development of vision measures against the natural loss expected to occur over the course of the 48 weeks, most measures showed reduced decline, and these reductions were significant for normal illumination”.
has been providing comprehensive information on alternative and conventional treatment for vision conditions since 1992. Search this blog and our Website for information on macular degeneration, glaucoma, cataracts, retinal conditions, myopia, and many other vision issues.
